What allergy symptoms does singulair treat

Common side effects include diarrhea, nausea, vomiting, mild rashes, asymptomatic elevations in liver enzymes, and fever. Unusual side effects include fatigue and malaise, behavioral changes, paresthesias and seizures, muscle cramps, and nose bleeds. Rare but serious side effects include behavioral changes (including suicidal thoughts), angioedema, erythema multiforme, and liver problems.[1]

In 2019, concerns for neuropsychiatric reactions were added to the label in the United Kingdom where the most frequently suspected were nightmares, depression, insomnia, aggression, anxiety and abnormal behaviour or changes in behaviour.[9]

FDA investigation

In September 2019, the Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee met to discuss a pediatric-focused safety review of neuropsychiatric events with montelukast.[10]

In June 2009, the FDA concluded a review into the possibility of neuropsychiatric side effects with leukotriene modulator drugs.

Although clinical trials only revealed an increased risk of insomnia, post-marketing surveillance showed that the drugs are associated with a possible increase in suicidal behavior and other side effects such as agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, irritability, restlessness, and tremor.[11]


Medical uses

Montelukast is used for a number of conditions including asthma, exercise induced bronchospasm, allergic rhinitis, and urticaria.[6] It is mainly used as a complementary therapy in adults in addition to inhaled corticosteroids, if inhaled steroids alone do not bring the desired effect.

It is also used to prevent allergic reactions and asthma flare-ups during the istration of intravenous immunoglobulin. It may also be used as an adjunct therapy in symptomatic treatment of mastocytosis.[7]

Montelukast is generally taken once a day with or without food.[8]


External links

  • ^«Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions». Retrieved 19 September 2019.
  • ^«NADAC as of 2018-12-19». Centers for Medicare and Medicaid Services. Retrieved 22 December 2018.
  • ^«FDA approves first generic versions of Singulair to treat asthma, allergies».

    3 August 2012. Retrieved 15 August 2012.

  • ^5,565,473
  • ^Scott JP, Peters-Golden M (September 2013). «Antileukotriene agents for the treatment of lung disease». Am. J. Respir. Crit.

    What allergy symptoms does singulair treat

    Care Med. 188 (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826.

  • ^Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR). Food and Drug istration. Published June 12, 2009. Accessed March 1, 2017.
  • ^FDA Joint Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee; Notice of Meeting
  • ^British national formulary : BNF 76 (76 ed.).

    Pharmaceutical Press. 2018. p. 269. ISBN .

  • ^Rubenstein, Sarah (April 28, 2008). «FDA Sneezes at Claritin-Singulair Combo Pill». The Wall Highway Journal.
  • ^«The Top 300 of 2019». clincalc.com. Retrieved 22 December 2018.
  • ^Singular patent details
  • ^«U.S. Reexamines Merck’s Singulair Patent». Thompson Reuters. May 28, 2009.
  • ^ abcdefghijklm«Montelukast Sodium Monograph for Professionals».

    Drugs.com. AHFS. Retrieved 23 December 2018.

  • ^Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]. Gentilly, France: Sanofi-aventis; August 2010. http://www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_products/Artesunate_and_Amodiquine.pdf
  • ^ ab«Montelukast 10 mg film coated tablets — Summary of Product Characteristics (SmPC) — (eMC)». Retrieved 23 December 2018.
  • ^Schering-Plough press release — Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
  • ^«Montelukast Sodium».

    The American Society of Health-System Pharmacists. Retrieved 3 April 2011.

  • ^«Merck Says U.S.

    What allergy symptoms does singulair treat

    Agency Upholds Singulair Patent». Thompson Reuters. December 17, 2009.

  • ^Montelukast article on Medline Plus https://www.nlm.nih.gov/medlineplus/druginfo/meds/a600014.html «Montelukast comes as a tablet, a chewable tablet, and granules to take by mouth. Montelukast is generally taken once a day with or without food.»
  • ^Cardet, J. C; Akin, C; Lee, M. J (2013).

    What allergy symptoms does singulair treat

    «Mastocytosis: Update on pharmacotherapy and future directions». Expert Opinion on Pharmacotherapy. 14 (15): 2033–2045. doi:10.1517/14656566.2013.824424. PMC 4362676. PMID 24044484.

  • ^German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis.

    What allergy symptoms does singulair treat

    2007;44(6):889-891. PID: 17304470

  • ^Li, Jie Jack (2006). «8». Laughing Gas, Viagra, and Lipitor: The Human Stories Behind the Drugs We Use. Oxford University Press. p. 234. ISBN . Retrieved 26 November 2017.

External links

External links

  • ^«Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions». Retrieved 19 September 2019.
  • ^«NADAC as of 2018-12-19».

    What allergy symptoms does singulair treat

    Centers for Medicare and Medicaid Services. Retrieved 22 December 2018.

  • ^«FDA approves first generic versions of Singulair to treat asthma, allergies». 3 August 2012. Retrieved 15 August 2012.
  • ^5,565,473
  • ^Scott JP, Peters-Golden M (September 2013).

    What allergy symptoms does singulair treat

    «Antileukotriene agents for the treatment of lung disease». Am. J. Respir. Crit. Care Med. 188 (5): 538–544. doi:10.1164/rccm.201301-0023PP. PMID 23822826.

  • ^Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR). Food and Drug istration. Published June 12, 2009. Accessed March 1, 2017.
  • ^FDA Joint Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee; Notice of Meeting
  • ^British national formulary : BNF 76 (76 ed.).

    Pharmaceutical Press. 2018. p. 269. ISBN .

  • ^Rubenstein, Sarah (April 28, 2008). «FDA Sneezes at Claritin-Singulair Combo Pill». The Wall Highway Journal.
  • ^«The Top 300 of 2019». clincalc.com. Retrieved 22 December 2018.
  • ^Singular patent details
  • ^«U.S. Reexamines Merck’s Singulair Patent». Thompson Reuters.

    May 28, 2009.

  • ^ abcdefghijklm«Montelukast Sodium Monograph for Professionals». Drugs.com. AHFS. Retrieved 23 December 2018.
  • ^Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics].

    Gentilly, France: Sanofi-aventis; August 2010. http://www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_products/Artesunate_and_Amodiquine.pdf

  • ^ ab«Montelukast 10 mg film coated tablets — Summary of Product Characteristics (SmPC) — (eMC)». Retrieved 23 December 2018.
  • ^Schering-Plough press release — Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
  • ^«Montelukast Sodium».

    The American Society of Health-System Pharmacists. Retrieved 3 April 2011.

  • ^«Merck Says U.S. Agency Upholds Singulair Patent». Thompson Reuters. December 17, 2009.
  • ^Montelukast article on Medline Plus https://www.nlm.nih.gov/medlineplus/druginfo/meds/a600014.html «Montelukast comes as a tablet, a chewable tablet, and granules to take by mouth. Montelukast is generally taken once a day with or without food.»
  • ^Cardet, J. C; Akin, C; Lee, M. J (2013). «Mastocytosis: Update on pharmacotherapy and future directions».

    Expert Opinion on Pharmacotherapy.

    What allergy symptoms does singulair treat

    14 (15): 2033–2045. doi:10.1517/14656566.2013.824424. PMC 4362676. PMID 24044484.

  • ^German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007;44(6):889-891. PID: 17304470
  • ^Li, Jie Jack (2006). «8». Laughing Gas, Viagra, and Lipitor: The Human Stories Behind the Drugs We Use. Oxford University Press. p. 234. ISBN . Retrieved 26 November 2017.

About Drugs A-Z

Drugs A-Z provides drug information from Everyday Health and our partners, as well as ratings from our members, every in one put.

Cerner Multum™ provides the data within some of the Basics, Side Effects, Interactions, and Dosage tabs. The information within the Reviews and FAQ tabs is proprietary to Everyday Health.

You can browse Drugs A-Z for a specific prescription or over-the-counter drug or glance up drugs based on your specific condition. This information is for educational purposes only, and not meant to provide medical advice, treatment, or diagnosis.

Remember to always consult your physician or health care provider before starting, stopping, or altering a treatment or health care regimen.

Every effort has been made to ensure that the information provided by on this sheet is precise, up-to-date, and finish, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. The information on this sheet has been compiled for use by healthcare practitioners and consumers in the United States and therefore neither Everyday Health or its licensor warrant that uses exterior of the United States are appropriate, unless specifically indicated otherwise. Neither Everyday Health nor its licensors endorse drugs, diagnose patients or recommend therapy.

The drug information above is an informational resource designed to help licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. Neither Everyday Health nor its licensor assume any responsibility for any aspect of healthcare istered with the aid of the information provided.

The information contained herein is not intended to cover every possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.

What allergy symptoms does singulair treat

If you own any questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Singulair (montelukast) is a once-daily prescription medication that was originally developed to treat asthma. Since then, however, it's been discovered that Singulair is also an effective treatment for allergic rhinitis (also known as hay fever).

Let's take a closer glance at Singulair, including its indications and side effects, and how its mechanism of action is unique to traditional medications for allergic rhinitis.

About Drugs A-Z

Drugs A-Z provides drug information from Everyday Health and our partners, as well as ratings from our members, every in one put.

Cerner Multum™ provides the data within some of the Basics, Side Effects, Interactions, and Dosage tabs. The information within the Reviews and FAQ tabs is proprietary to Everyday Health.

You can browse Drugs A-Z for a specific prescription or over-the-counter drug or glance up drugs based on your specific condition. This information is for educational purposes only, and not meant to provide medical advice, treatment, or diagnosis. Remember to always consult your physician or health care provider before starting, stopping, or altering a treatment or health care regimen.

Every effort has been made to ensure that the information provided by on this sheet is precise, up-to-date, and finish, but no guarantee is made to that effect.

Drug information contained herein may be time sensitive. The information on this sheet has been compiled for use by healthcare practitioners and consumers in the United States and therefore neither Everyday Health or its licensor warrant that uses exterior of the United States are appropriate, unless specifically indicated otherwise. Neither Everyday Health nor its licensors endorse drugs, diagnose patients or recommend therapy. The drug information above is an informational resource designed to help licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. Neither Everyday Health nor its licensor assume any responsibility for any aspect of healthcare istered with the aid of the information provided. The information contained herein is not intended to cover every possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you own any questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Singulair (montelukast) is a once-daily prescription medication that was originally developed to treat asthma.

Since then, however, it's been discovered that Singulair is also an effective treatment for allergic rhinitis (also known as hay fever).

Let's take a closer glance at Singulair, including its indications and side effects, and how its mechanism of action is unique to traditional medications for allergic rhinitis.


Society and culture

Patents

Singulair was covered by U.S. Patent No. 5,565,473[15] which expired on August 3, 2012.[16] The same day, the FDA approved several generic versions of montelukast.[17]

The United States Patent and Trademark Office launched a reexamination of the patent covering Singulair on May 28, 2009.

The decision was driven by the discovery of references that were not included in the original patent application process. The references were submitted through Article One Partners, an online research community focused on finding literature relating to existing patents. The references included a scientific article produced by a Merck employee on the athletic ingredient in Singulair. A previously filed patent had been submitted in the same technology area.[18] Seven months later the U.S. Patent and Trademark Office sure that the patent in question was valid based on the initial reexamination and new information provided, submitting their decision on December 17, 2009.[19]

Use with loratadine

Schering-Plough and Merck sought permission to market a combined tablet with loratadine and montelukast, as numerous people combine the two themselves.

However, the FDA has found no benefit from a combined pill for seasonal allergies over taking the two drugs in combination,[20] and on April 25, 2008, issued a not-approvable letter for the combination.[21]

Names

The Mont in montelukast stands for Montreal, the put where Merck (MSD) developed the drug.[22]

Montelukast is sold under a variety of brand names including Montenaaf (NAAFCO Pharma) Montelon-10 (Apex), Montene (Square), Montair-10, Montelo-10, Monteflo, and Tukast L in India, Reversair (ACI Bangladesh), Miralust, Montiva, Provair, Montril, Lumona, Lumenta, Arokast and Trilock in Bangladesh, Ventair in Nepal, Montika in Pakistan, Montelair in Brazil, Zykast in the Philippines though combined with levocetirizine, Notta in Turkey, Topraz in South Africa and AirOn in Venezuela.


Pharmacology

Main article: Leukotriene receptor antagonist

Montelukast is in the leukotriene receptor antagonist family of medications.[2] It works by blocking the action of leukotriene D4 in the lungs resulting in decreased inflammation and relaxation of smooth muscle.[2]

Montelukast functions as a leukotriene receptor antagonist (cysteinyl leukotriene receptors) and consequently opposes the function of these inflammatory mediators; leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and mucus secretion in asthma and COPD.[14] Leukotriene receptor antagonists are sometimes colloquially referred to as leukasts.

Two genes of interest are ALOX5 and LCT4S.[citation needed][clarification needed]


Drug interactions

Montelukast has extremely few drug-drug interactions. This is due to the lack of off-target affinity towards other targets in the body where it might exert an effect. However, it is significant to note that montelukast is an inhibitor of the drug metabolizing enzyme CYP2C8. Therefore, it is theoretically possible that the combination of montelukast with a CYP2C8 substrate (e.g.

amodiaquine, an anti-malarial drug) could increase the plasma concentrations of the substrate.[12][13]


RELATED VIDEO: